• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Shuttle Pharmaceuticals Holdings Inc.

    5/12/26 4:15:06 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SHPH alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
     
    Check the appropriate box:
     
    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under §240.14a-12

     

    SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
    (Name of Registrant as Specified In Its Charter)
     
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):
     
    ☒ No fee required.
       
    ☐ Fee paid previously with preliminary material.
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     
     

     

    SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

    401 Professional Drive, Suite 260

    Gaithersburg, Maryland 20879

     

    SUPPLEMENT TO

    NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

    AND PROXY STATEMENT DATED APRIL 20, 2026

    FOR ANNUAL MEETING OF STOCKHOLDERS

    TO BE HELD ON MAY 21, 2026

     

    This Supplement provides updated information with respect to the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation, to be held on Thursday, May 21, 2026 at 12:00 p.m. Eastern Time. Unless the context otherwise requires, references to the “Company,” “we,” and “our” refer to Shuttle Pharmaceuticals Holdings, Inc.

     

    The Company previously distributed its Notice of Annual Meeting of Stockholders and Proxy Statement (the “Notice and Proxy Statement”) for the Annual Meeting. This Supplement, which describes a recent change in the proposed nominees for election to the Company’s Board of Directors (the “Board”), should be read in conjunction with the Notice and Proxy Statement.

     

    Withdrawal of Nominee for Election as Director

     

    As previously disclosed by the Company on a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2026, Oleh Nabyt, previously a director of the Company, notified the Company of his decision to resign from the Board, effective immediately. Mr. Nabyt’s decision to resign from the Board was not related to a disagreement with the Company over any of its operations, policies or practices. Accordingly, the nomination of Mr. Nabyt for re-election to the Board at the Annual Meeting has been withdrawn.

     

    In light of Mr. Nabyt’s resignation from the Board and the subsequent withdrawal of his name as a nominee for re-election to the Board, Proposal No. 1 in the Notice and Proxy Statement now proposes to elect the remaining four director nominees named in the Proxy Statement to hold office until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified.

     

    THE BOARD RECOMMENDS A VOTE FOR THE ELECTION OF EACH OF THE REMAINING FOUR DIRECTOR NOMINEES

     

    Voting Matters

     

    If you have already voted, you do not need to take any action unless you wish to change your vote. Proxy voting cards already returned by stockholders will remain valid and will be voted at the Annual Meeting unless revoked.

     

    If we receive a proxy instruction from you before the Annual Meeting, your shares will be voted for the directors nominated by the Board as instructed by you, except that votes will not be cast for Oleh Nabyt because he has resigned from the Board and is no longer standing for re-election. If you have not yet voted, please complete the Proxy Card or submit your voting instructions, disregarding Mr. Nabyt’s name as a nominee for election as director.

     

    None of the other agenda items presented in the Notice and Proxy Statement are affected by this Supplement, and shares represented by proxy instructions returned before the Annual Meeting will be voted with respect to all other matters properly brought before the Annual Meeting in accordance with those voting instructions.

     

    Information regarding how to vote your shares, or revoke your proxy or voting instructions, is available in the Proxy Statement.

     

      By order of the Board of Directors,
       
      Christopher Cooper
      Interim Chief Executive Officer

     

     

     

    Get the next $SHPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SHPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site

    United Dogecoin looks to have its miners operational within approximately 60 days, leveraging low-cost, renewable energy, on its path to being the market's largest Dogecoin miner by hashrateGaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle"), has completed two significant milestones on its projected path to market scale and operational excellence.United Dogecoin has purchased its first fleet of ElphaPex DG1+ mining units, which the Company believes are among the most powerful and efficient D

    6/26/26 8:00:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Dogecoin Advances Data Centre and Power Infrastructure Strategy to Support DOGE Mining and AI Hosting

    United Dogecoin shares insights on its digital infrastructure strategy, aimed at expanding revenue opportunities and supporting long-term shareholder value creation.Gaithersburg, Maryland--(Newsfile Corp. - June 25, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining and digital infrastructure company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle"), has initiated an evaluation of proprietary data centre and power generation opportunities designed to support long-term DOGE mining operations and future AI infrastructure workloads. Alongside this exploration, the Company continues to move toward ele

    6/25/26 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs

    Initial Mining Fleet Targeted for Deployment Within 60 Days of Receipt; To Mine DOGE and LTC and Accumulate Mined Coins as Long-Term Treasury AssetsGaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining operations. As previously reported on Shuttle's Current R

    5/14/26 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp sold $372,704 worth of shares (83,149 units at $4.48), closing all direct ownership in the company (SEC Form 4)

    4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    7/15/26 3:36:26 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Hrt Financial Lp bought $30,212 worth of shares (8,997 units at $3.36), increasing direct ownership by 17% to 61,271 units (SEC Form 4)

    4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    7/13/26 2:34:01 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Hrt Financial Lp claimed ownership of 60,540 shares (SEC Form 3)

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    7/13/26 2:21:33 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $30,212 worth of shares (8,997 units at $3.36), increasing direct ownership by 17% to 61,271 units (SEC Form 4)

    4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    7/13/26 2:34:01 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Hrt Financial Lp bought $27,793 worth of shares (7,851 units at $3.54) and sold $31,667 worth of shares (9,022 units at $3.51), decreasing direct ownership by 1% to 81,385 units (SEC Form 4)

    4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    7/7/26 4:23:17 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Hrt Financial Lp bought $13,065 worth of shares (3,959 units at $3.30), increasing direct ownership by 5% to 82,556 units (SEC Form 4)

    4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    7/2/26 1:37:35 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    SEC Filings

    View All

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    6/30/26 7:27:10 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    6/11/26 5:00:26 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/27/26 9:00:14 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Leadership Updates

    Live Leadership Updates

    View All

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

    GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

    6/4/25 4:01:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

    GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities. "I am excited to welcome Christopher Cooper as Co-CEO of

    3/12/25 6:20:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Shuttle Pharmaceuticals Holdings Inc. (Amendment)

    SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    10/17/23 6:57:47 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Shuttle Pharmaceuticals Holdings Inc.

    SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    5/30/23 5:30:57 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care